Sanofi and Janssen Partner to Develop Vaccine for E.coli

Sanofi has announced a collaboration with Janssen, a part of Johnson & Johnson, to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli (ExPEC). Both companies will co-fund the research and development (R&D) costs for the vaccine.

As part of the agreement, Sanofi will make an upfront payment of $175 million to Janssen, with additional payments to follow upon the achievement of development and commercial milestones. This partnership combines the strengths and expertise of both pharmaceutical companies in developing vaccines and aims to address the persistent challenge of ExPEC infections.

Extra-intestinal pathogenic E.coli is a type of E.coli that can cause severe infections outside of the intestines, including urinary tract infections and bloodstream infections. These infections are a significant global health issue and can lead to complications, such as sepsis.
The collaboration between Sanofi and Janssen brings together the resources and capabilities of two leading pharmaceutical companies to accelerate the development of a potential vaccine for ExPEC. By combining their efforts, the companies hope to make significant progress in preventing and treating ExPEC infections.

This partnership reflects Sanofi’s commitment to advancing their vaccine portfolio and addressing unmet medical needs. Through collaborations with other industry leaders, Sanofi aims to leverage their expertise and resources to bring innovative solutions to patients.

Follow Emirates 24|7 on Google News.